Cantor Fitzgerald Releases a Buy Rating on Amarin

By Jason Carr

In a report released today, Chiara Russo from Cantor Fitzgerald reiterated a Buy rating on Amarin (NASDAQ: AMRN), with a price target of $6. The company’s shares closed last Friday at $3.29, close to its 52-week high of $3.65.

Russo commented:

“Different Targets, Risk Remains: PCSK9s are a new class of injectable drug for lowering LDL-C levels for patients when statin therapy is not adequate. Vascepa, comparatively, is an ultra pure form of omega-3, icosapent ethyl acid (EPA) that reduces triglyceride levels. Both are intended to reduce relative CV risk beyond that of statin therapy. We note that, although the recent data for Repatha show significant LDL-C lowering, there was less-pronounced CV risk benefit than may have been expected.”

According to, Russo is a 3-star analyst with an average return of 1.2% and a 46.5% success rate. Russo covers the Healthcare sector, focusing on stocks such as Paratek Pharmaceuticals, Axsome Therapeutics Inc, and Flexion Therapeutics.

Amarin has an analyst consensus of Strong Buy, with a price target consensus of $10.

The company has a one year high of $3.65 and a one year low of $1.40. Currently, Amarin has an average volume of 1.7M.

Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is neutral on the stock. Most recently, in November 2016, Joseph T. Kennedy, the General Counsel of AMRN sold 122,358 shares for a total of $371,968.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Amarin Corp. Plc is a biopharmaceutical company, which engages in the commercialization and development of therapeutics for cardiovascular health. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.